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Abstract
Background: The identification and characterization of several interferon (IFN)-induced cellular HIV-1 restriction factors,
defined as host cellular proteins or factors that restrict or inhibit the HIV-1 life cycle, have provided insight into the IFN
response towards HIV-1 infection and identified new therapeutic targets for HIV-1 infection. To further characterize the
mechanism underlying restriction of the late stages of HIV-1 replication, we assessed the ability of IFNbeta-induced
genes to restrict HIV-1 Gag particle production and have identified a potentially novel host factor called HECT domain
and RCC1-like domain-containing protein 5 (HERC5) that blocks a unique late stage of the HIV-1 life cycle.
Results: HERC5 inhibited the replication of HIV-1 over multiple rounds of infection and was found to target a late
stage of HIV-1 particle production. The E3 ligase activity of HERC5 was required for blocking HIV-1 Gag particle
production and correlated with the post-translational modification of Gag with ISG15. HERC5 interacted with HIV-1
Gag and did not alter trafficking of HIV-1 Gag to the plasma membrane. Electron microscopy revealed that the
assembly of HIV-1 Gag particles was arrested at the plasma membrane, at an early stage of assembly. The
mechanism of HERC5-induced restriction of HIV-1 particle production is distinct from the mechanism underlying
HIV-1 restriction by the expression of ISG15 alone, which acts at a later step in particle release. Moreover, HERC5
restricted murine leukemia virus (MLV) Gag particle production, showing that HERC5 is effective in restricting Gag
particle production of an evolutionarily divergent retrovirus.
Conclusions: HERC5 represents a potential new host factor that blocks an early stage of retroviral Gag particle
assembly. With no apparent HIV-1 protein that directly counteracts it, HERC5 may represent a new candidate for
HIV/AIDS therapy.
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Background
Several IFN-induced proteins have been identified as cor-
relates of HIV-1 infection and disease progression [1-4].
A few of these factors have already been shown to exhibit
antiviral activity towards HIV-1, such as apolipoprotein B
mRNA-editing enzyme catalytic polypeptide (APOBEC)
3G, bone marrow stromal antigen 2 (BST2)/tetherin and
tripartite motif-containing protein 22 (TRIM22)
(reviewed in [5]). To identify and characterize additional
potential host factors, we surveyed IFNbeta (IFNb)-
induced genes from two previous studies [6,7] for poten-
tial anti-HIV-1 activity and identified HERC5 as a new
h o s tf a c t o rt h a tm a yb l o c kal a t es t a g eo ft h eH I V - 1l i f e
cycle.
The herc5 gene is one of six human herc family genes
located on chromosome 4 and flanked by herc6 and herc3.
The HERC5 protein is 1024 amino acids in length and
contains a Regulator of Chromosome Condensation 1
(RCC1)-like domain (RLD) at its amino-terminus, followed
by a unique Spacer region that does not share homology
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boxyl-terminus [8-10]. The function of the RLD domain is
unknown; however, it appears to be important, but not
essential, for the conjugation of ISG15 to cellular proteins
[6]. Also, the predicted tertiary structure of the RLD clo-
sely resembles the crystal structure of the human RCC1
protein (reviewed in [11,12]). The Spacer region contains
numerous a-helices, and its function is unknown. The
HECT domain is typically found in E3 ligases, which oper-
ate in conjunction with unique E1 “activating” and E2
“conjugating” enzymes to transfer ubiquitin or ubiquitin-
like proteins, such as ISG15, to specific cellular substrates.
HERC5 is the main E3 ligase for the conjugation of
ISG15 to proteins in human cells and works together
with the E1 activating protein Ube1L as well as the E2
conjugating protein UbcH8 to conjugate ISG15 onto
target proteins [6,13,14]. Cysteine 994 of the HERC5
HECT domain is essential for this E3 ligase activity of
HERC5 [13]. Two reports have also identified HERC5 as
an E3 ubiquitin ligase [15,16]. HERC5 is ubiquitously
expressed with the highest levels of expression observed
in the testis. HERC5 is up-regulated in a variety of pri-
mary cells and immortalized cell lines by interferon,
lipopolysaccharide, tumor necrosis factor a,a n di n t e r -
leukin-1b [6,13,16]. Moreover, HERC5 broadly targets
newly synthesized proteins for ISG15 conjugation, and
many endogenous targets of HERC5 have been identi-
fied that function in a variety of cellular pathways
including RNA splicing, chromatin remodeling/polII
transcription, cytoskeleton organization and regulation,
stress responses, translation, glycolysis, interferon signal-
ing and antiviral responses [17-22]. Here, we show that
HERC5 inhibits HIV-1 replication by targeting a unique
step of HIV-1 particle assembly at the plasma
membrane.
Results
HERC5 inhibits HIV-1 particle production
HERC5 is the main cellular E3 ligase that conjugates
ISG15 to proteins and can target newly synthesized pro-
teins, including foreign proteins [6,13,21]. Therefore, we
tested the ability of HERC5 to restrict the release of
newly made infectious HIV-1 particles. We co-trans-
fected 293T cells with empty vector or plasmids encoding
replication-competent HIV-1 (pR9) and HERC5. Cells
expressing HERC5 released 4.0-fold less infectious virus
than the control cells after a single round of replication
(P = 0.008, paired t test) (Figure 1A). Similar results were
also obtained in HOS-CD4/CXCR4 cells, which support
robust HIV-1 replication. HOS-CD4/CXCR4 cells
expressing HERC5 released 10.8-fold less infectious HIV-
1 particles into the supernatant after multiple rounds of
replication (P = 0.001, paired t test) (Figure 1B). Similar
levels of inhibition of HIV-1 particle release after single
and multiple rounds of replication were observed by
Western blot analysis (Figure 1C). There was no signifi-
cant difference in the viability of cells expressing HERC5
compared to the control cells (90.2% ± 4.4% SD versus
92.0% ± 4.3% SD respectively; P > 0.05, paired t test).
To assess the impact of reduced levels of HERC5 on
HIV-1 particle production, we depleted HERC5 using
short hairpin ribonucleic acid (shRNA) and measured the
amount of HIV-1 particles released into the supernatant.
293T cells, which express basal levels of HERC5, were
transiently co-transfected for 24 hours with either
pLKO.1/scrambledshRNA or pLKO.1/HERC5shRNA and
pR9. Cells expressing HERC5 shRNA exhibited 2.3-fold
less HERC5 RNA than the control cells expressing
scrambled shRNA (Figure 1D and 1E). As a control for
specificity, RNA levels of the related herc3 gene were
tested and found to be unaffected by the scrambled or
HERC5 shRNA (Figure 1D and 1E). Accumulation of
HIV-1 particles in the supernatant and cell pellets was
monitored by Western blot using anti-p24CA (Figure
1F). Cells knocked down for HERC5 expression released
1.9-fold more HIV-1 particles into the supernatant com-
pared to the control cells (Figure 1F and 1G). No sub-
stantial change in the intracellular Pr55Gag protein level
was detected. Similar results were observed in HeLa cells,
which also express basal levels of HERC5 (data not
shown).
HERC5 blocks HIV-1 Gag particle production and this
block correlates with the ISGylation of Gag
Gag is the major structural polyprotein of HIV-1 that
drives virion formation and can assemble and bud from
cells in the absence of all other HIV-1 proteins as Gag-
only particles [23]. Therefore, we asked if HERC5 could
conjugate ISG15 to Gag, and in so doing, interfere with
Gag particle production. To test this, we used a single-
cycle HIV-1 Gag-only particle release assay in U2OS cells,
which do not express HERC5 mRNA basally or after IFNb
treatment, thereby providing a HERC5 null background
(reference [14] and data not shown). The Gag-only particle
release assay involved the co-transfection of plasmids
encoding codon-optimized HIV-1 Gag with or without
HERC5 and the measurement of the Gag-only particles
released into the supernatant by quantitative Western
blotting. To enhance detection of Gag modified with
ISG15, plasmids encoding histidine-tagged ISG15, Ube1L
and UbcH8 (referred to hereafter as the conjugation sys-
tem (CS)), were included in the transfections.
As shown in Figure 2A, Western blot analysis revealed
that cells expressing HERC5 + CS released substantially
less Gag-only particles into the supernatant than the con-
trol cells. In contrast, cells expressing HERC5-C994A
(defective for its E3 ligase activity) + CS failed to inhibit
the release of Gag-only particles. Western blot analysis of
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Page 2 of 17Gag protein expression in cell lysates revealed similar
levels of Gag (55 kDa) in all samples. Notably, more
slowly migrating Gag species (~85 kDa and ~110 kDa)
were detected in cells expressing HERC5 + CS. These
slowly migrating Gag bands were not present in the
HERC5-C994A + CS samples, suggesting that the E3
ligase activity of HERC5 was required for generating the
more slowly migrating Gag species (Figure 2A). Western
blot analysis of the cell lysates revealed the presence of
ISG15 conjugates in cells transfected with HERC5 + CS,
but not cells transfected with empty vector or HERC5-
C994A, as previously shown [13]. The sizes of these
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Figure 1 HERC5 restricts a late stage of HIV-1 replication. A, Inhibition of HIV-1 particle production. 293T cells were co-transfected with pR9
and either empty plasmid or pHERC5. Twenty-four hours after transfection, infectious HIV-1 virions released into the supernatant were quantified
using GHOST(3) indicator cells. B, Inhibition of HIV-1 replication. HOS-CD4/CXCR4 cells were co-transfected with plasmids encoding a replication-
competent HIV-1 provirus (R9) and HERC5 or an empty vector control. HIV-1 virions released into the supernatant were pelleted 72 hours after
transfection and analyzed by Western blotting using anti-p24CA antibody. p24CA levels were quantified densitometrically. C, Representative
Western blot using anti-p24CA of HIV-1 particles released into the supernatant. Data shown are the average of at least two independent
experiments performed in triplicate. D-G, 293T cells were co-transfected with pLKO.1/scrambledshRNA or pLKO.1/HERC5shRNA and pR9. Twenty-four
hours after transfection, HIV-1 particles released into the supernatant, cellular RNA and cellular protein were isolated. HERC5, HERC3 and b-actin
RNA were detected by reverse transcription polymerase chain reaction (RT-PCR) (D) and quantified densitometrically (E). HIV-1 particles released
into the supernatant and intracellular Pr55Gag protein were detected by Western blotting using anti-p24CA (F) and quantified densitometrically
(G). Data shown are representative of at least two independent experiments.
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Figure 2 HERC5 restricts HIV-1 Gag particle production by a mechanism dependent on its E3 ligase activity. A, U2OS cells were co-
transfected with pGag, pUbe1L, pUbcH8, pMyc-ISG15 and either empty plasmid, pHERC5 or pHERC5-C994A. Gag particles released into the
supernatant and intracellular Gag protein expression were analyzed after 24 hours by quantitative Western blotting using anti-p24CA and anti-b-
actin as a loading control. The same blot was stripped and tested for ISG15 conjugates using anti-myc (bottom blot). B, Cells were co-
transfected with empty plasmid or pHERC5 and pUbe1L, pUbcH8, pHis-ISG15 and pGag. Cells were lysed 72 hours later and histidine-tagged
proteins were purified using nickel agarose. Purified proteins were resolved using SDS-PAGE and subjected to Western blotting using anti-p24CA.
C, Cells were co-transfected with empty vector or pHERC5, pUbe1L, pUbcH8, pHis-ISG15 and pGag with or without pUbp43. Gag particles
released into the supernatant and intracellular Gag protein expression were analyzed after 72 hours by quantitative Western blotting using anti-
p24CA or anti-b-actin. D, In a similar transfection as in C, histidine-tagged proteins were purified from cell extracts using nickel agarose and
subjected to Western blotting using anti-p24CA. The two lanes were digitally separated from the same image. Numerical values on the blots
display the densitometric quantification of the specified bands. All Western blots shown are representative of at least two independent
experiments.
Woods et al. Retrovirology 2011, 8:95
http://www.retrovirology.com/content/8/1/95
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jugation of two or more ISG15 proteins (one ISG15 =
~15 kDa), although non-linear decreases in the electro-
phoretic mobility of proteins conjugated with ISG15 in
SDS-PAGE gels have been previously reported [24,25].
The identities of the slowly migrating Gag species were
confirmed to be Gag after immunoprecipitation and pro-
tein identification using matrix-assisted laser desorption/
ionization mass spectrometry (MALDI-MS). There was
no significant difference in the viability of cells expressing
HERC5 + CS compared to the control cells (92.0% ± 4.3%
SD versus 90.2% ± 4.4% SD respectively; P >0 . 0 5 ,p a i r e d
t test).
To determine if the more slowly migrating bands of Gag
contained conjugates of ISG15, we co-expressed Gag and
HERC5 with histidine-tagged ISG15 and the CS for 72
hours and then incubated the cell lysate with nickel agar-
ose under non-denaturing conditions. Western blot analy-
sis of the purified proteins using anti-p24CA revealed the
presence of several species of Gag ranging from ~55 kDa
to ~200 kDa in size (Figure 2B), including the ~85 kDa
and ~110 kDa bands detected in the whole cell lysate (Fig-
ure 2A). Notably, when the ISG15ylated Gag species was
purified under non-denaturing conditions, a substantial
amount of 55 kDa Gag species was co-purified, suggesting
that Gag species conjugated with ISG15 can interact with
the 55 kDa unmodified Gag (Figure 2B). It is unknown
why the ~85 kDa Gag species was more abundant than
the ~110 kDa species after purification with the nickel
agarose (compared to the levels observed in the cell lysate
(Figure 2A). We have noticed that the ~110 kDa species is
more abundant if Gag is purified 48 hours after transfec-
tion instead of after 72 hours, possibly indicating that
some of the modifications are labile.
To assess the importance of ISG15ylation in restricting
Gag particle release, we co-expressed HERC5 + CS with
the ISG15-specific deconjugating enzyme Ubp43 and
assessed whether Ubp43 could rescue restriction imposed
by HERC5 [26]. Quantitative Western blot analysis of
Gag particles released into the supernatant showed that
Ubp43 abolished HERC5-induced restriction, despite the
presence of similar levels of intracellular Gag (Figure 2C).
T h er e s c u eo fG a gp a r t i c l er e l e a s eb yU b p 4 3c o r r e l a t e d
with a 7.2-fold reduction in intracellular ISG15ylated Gag
(Figure 2D).
Intracellular localization of HERC5 and HIV-1 Gag
Confocal immunofluorescence microscopy of IFNb-trea-
ted PBMCs, human Jurkat cells, and immortalized mur-
ine mature dendritic cells (DC2.4) revealed that HERC5
localized to the cytoplasm in punctate bodies in each of
the cell types (Figure 3A), consistent with the pattern of
localization observed for HERC5 in human mammary
epithelial cells [15]. Recently, it was shown biochemically
in HeLa cells, but not microscopically, that HERC5 co-
fractionated with polysomes due to an association with
the 60S ribosomal subunit [21]. Consistent with this
report, we observed that 59.9% ± 0.12% SD of HERC5
co-localized with polyribosomes in IFNb-treated Jurkat
cells using confocal immunofluorescence microscopy
(mean Pearson’s coefficient = 0.855; n = 10) (Figure 3B).
Similar observations were made in HOS-CD4/CXCR4
cells where 61.7% ± 0.13% SD of IFNb-induced HERC5
co-localized with ribosomes (mean Pearson’s coefficient =
0.863; n =1 0 ) .
To determine if HERC5 and HIV-1 Gag co-localize in
cells, we co-transfected plasmids encoding Gag-only
(pGag) or replication-competent HIV-1 (pR9) with and
without HERC5 + CS. Forty-eight hours after transfection,
the localization of Gag and HERC5 protein was assessed
in U2OS cells by examining optical slices through the cen-
ter of cells. Gag expressed in the absence of HERC5 exhib-
ited predominantly punctate fluorescence at the plasma
membrane, consistent with the location of assembly and
budding of Gag particles (Figure 3C). HERC5 expressed in
the presence or absence of the conjugation system loca-
lized predominantly in the cytoplasm in punctate bodies
(Figure 3C). When Gag was co-expressed with HERC5 +
CS, Gag localized predominantly at the plasma membrane
(Figure 3D). Interestingly, a substantial amount of HERC5
accumulated near the plasma membrane where 65.2% ±
0.21% SD of Gag expressed from pR9 co-localized with
HERC5 (mean Pearson’s coefficient = 0.324; n = 21) and
53.1% ± 0.16 SD of Gag expressed from pGag co-localized
with HERC5 (mean Pearson’s coefficient = 0.336; n = 15).
Since it was recently shown that HERC5 can conjugate
ISG15 to exogenously expressed foreign proteins [21], we
asked whether we could detect an interaction between
flag-tagged HERC5 and HIV-1 Gag biochemically. Flag-
tagged HERC5 + CS or flag-tagged HERC5-C994A + CS
were co-expressed with replication-competent HIV-1 (R9)
in HeLa cells. Forty-eight hours post-transfection, cells
were lysed under non-denaturing conditions and subjected
to co-immunoprecipitation using anti-p24CA. Western
blot analysis of the precipitated proteins revealed that both
flag-tagged HERC5 and HERC5-C994A co-precipitated
with HIV-1 Gag (Figure 3E). Despite similar input levels
of intracellular Gag, more Gag was consistently immuno-
precipitated in the presence of HERC5 compared to the
control and HERC5-C994A. Similar results were obtained
with 293T cells (data not shown).
HERC5 inhibits an early stage of Gag assembly
We then utilized transmission electron microscopy (TEM)
to examine HIV-1 Gag particles assembling at the plasma
membrane in the presence or absence of HERC5. As nor-
mally seen phenotypically with TEM micrographs of nega-
tively-stained samples, HIV-1 Gag particle assembly at the
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Figure 3 Intracellular localization of IFNb-treated HERC5 and HIV-1 Gag. A, Localization of endogenous HERC5 (red) in IFNb-treated (500
units/ml for 16 hours) PBMCs (scale bar = 5 μm), Jurkat cells (scale bar = 5 μm), and murine dendritic cells (scale bar = 10 μm). Images shown
are representative of at least 2 independent experiments. B, Localization of endogenous ribosomes (green) and HERC5 (red) in control Jurkat
cells or IFNb-treated Jurkat cells (scale bar = 5 μm). Localization of Gag alone (red) or HERC5 (green) +/- CS (C), or co-expression of Gag and
HERC5 + CS (D) in U2OS cells 48 hours after transfection. Scale bars = 20 μm. Images shown are representative of at least 3 independent
experiments. E, HeLa cells were co-transfected with pR9, pUbe1L, pUbcH8, and pMyc-ISG15 with or without pFlag-HERC5 or pFlag-HERC5-C994A.
Gag was immunoprecipitated under non-denaturing conditions using anti-p24CA. Precipitated proteins were resolved using SDS-PAGE and
subjected to Western blotting using anti-Flag or anti-p24CA. 10% of the input lysates was subjected to Western blotting using anti-p24CA and
anti-b-actin on the same blot. HERC5 protein was undetectable in the 10% input lysates.
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protein at the plasma membrane, which is visualized as
small electron-dense regions at the plasma membrane
often seen as small buds with the diameter of an immature
Gag shell ~150-200 nm (step I). This is followed by the
formation of more pronounced half-spherical particles
protruding from the plasma membrane (step II), more
extensive budding with nearly complete spherical particles
that are still contiguous with the cytoplasm via a stalk-like
("lollipop”) structure (step III), scission of viral and cellular
membranes (step IV), and finally release and distancing of
the HIV-1 Gag particle from the plasma membrane (step
V) (Figure 4A).
To differentiate between the various stages of assem-
bly, budding and release, we examined TEM images of
mock transfected U2OS cells and cells transfected with
plasmids encoding codon-optimized HIV-1 Gag with or
without HERC5 + CS. U2OS cells were chosen because
of their HERC5 null background and that HIV-1 parti-
cles assemble and bud at their plasma membrane nor-
mally. As shown in Figure 4B, the mock control cells
exhibited a relatively unperturbed plasma membrane,
the absence of electron-dense accumulations/patches
and budding structures at t h ep l a s m am e m b r a n e .I n
contrast, cells expressing Gag in the absence of HERC5
+ CS exhibited substantial perturbations of the plasma
membrane and budding Gag-only particles. The Gag-
only particles appeared as enveloped, spherical particles
that resembled immature HIV virions but more hetero-
geneous in size (up to ~500 nm in diameter). This
observation is in agreement with previously published
results [27]. Strikingly, cells expressing Gag in the pre-
sence of HERC5 + CS yielded substantially less Gag-
only particles and exhibited pronounced electron-dense
staining at the plasma membrane appearing in a polar-
ized region of the plasma membrane or at regions of
cell-cell-contact (Figure 4B).
To determine if the pronounced accumulation of Gag
at the plasma membrane was due to gross over-expres-
sion from the cytomegalovirus (CMV) promoter-driven
codon-optimized Gag (pGag), we performed a similar
TEM experiment, except that we transfected a plasmid
encoding replication-competent proviral HIV-1 (pR9).
This plasmid expresses biologically relevant levels of
wild type Gag (in addition to all other HIV-1 proteins)
from the HIV-1 long terminal repeat promoter. As seen
in Figure 4C, the plasma membrane of mock transfected
cells exhibited a relatively unperturbed profile with no
viral particles released from the plasma membrane,
whereas cells expressing HIV-1 alone produced numer-
ous predominantly homogeneous particles (~100-150
nm in diameter). Cells transfected with pR9 and
pHERC5 + CS released substantially less HIV-1 particles
compared to cells expressing R9 only. Notably, numer-
ous cells exhibited electron-dense regions resembling
early HIV-1 Gag assembly structures at the plasma
membrane, with the absence of budded “lollipop” struc-
tures, extracellular virions, and intracellular virions. The
electron dense patches accumulated in a polarized
region of the plasma membrane or at regions of cell-cell
contact. The electron-dense regions of the early budding
structures are ~150-200 nm in diameter, which is con-
sistent with the diameter of a budding immature Gag
shell [28]. To confirm that Gag protein accumulated in
HIV-1 Gag particles and electron dense regions at the
plasma membrane, we performed immunogold-labeling
u s i n ga n t i - p 2 4 C A .A ss h o w ni nF i g u r e4 D ,G a gw a s
observed to specifically localize in each of these regions.
Quantification of immunogold localization on the elec-
tron microscopic thin sections from cells expressing
H E R C 5+C Sa n dG a g - o n l yo rR 9s h o w e dt h a tt h eg o l d
labeling distribution was significantly different from a
random distribution (Chi square analysis, X
2 =3 1 4 . 8 ,d f
=2 ,P < 0.0001) (Table 1) (see Methods for details).
HERC5-induced restriction of Gag particle production is
distinct from ISG15-only restriction
Three reports suggest that ectopic expression of the CS
only (minus HERC5) restricts HIV-1 Gag particle bud-
ding and/or release [29-31]. Since HERC5 is the main
enzyme responsible for the conjugation of ISG15 to pro-
teins, we asked if HERC5 was the E3 ligase responsible
for the restriction of Gag-only particle release induced
by ISG15 expression. To address this question, we per-
formed a single-cycle Gag-only release assay by co-
expressing Gag + CS only in U2OS cells (which lack
HERC5 expression). Consistent with the three previous
published reports [29-31], we observed that the CS
blocked Gag particle production without affecting the
levels of intracellular Gag protein (data not shown).
To determine if the inhibition of Gag particle produc-
tion by the CS alone resembled the inhibition of Gag
particle production induced by CS + HERC5, we exam-
ined TEM micrographs of cells expressing replication-
competent HIV-1 (R9) + CS only. Analysis of cells
expressing R9 + CS revealed an accumulation of appar-
ently fully enveloped immature virions on the surface of
the cell in addition to virions within intracellular com-
partments (Figure 5A). Virions found on the cell surface
were closely associated with each other as doublet parti-
cles or in long chains. This phenotype is in contrast
with that observed when HIV-1 is expressed in the pre-
sence of HERC5 + CS (Figure 4C).
We also assessed the intracellular localization of Gag
in these cells by confocal immunofluorescence micro-
scopy analysis. As shown in Figure 5B, control cells
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Page 8 of 17transfected with pGag + empty vector exhibited numer-
ous punctate signals predominantly at the plasma mem-
brane and regions of cell-cell contact, consistent with
the site of Gag particle budding. Similar to the control
cells, cells transfected with pGag + CS + pHERC5
exhibited an accumulation of Gag predominantly at the
plasma membrane and regions of cell-cell contact. Inter-
estingly, in cells transfected with pGag + CS, Gag accu-
mulated at the plasma membrane and in the cytoplasm
as large clusters (Figure 5B).
Quantitative analysis of cells co-expressing Gag + CS
-HERC5 revealed that 34.5% ± 3.5% SD of the cells con-
tained Gag localized in the cytoplasm as large clusters.
This is significantly more than cells expressing Gag only
or Gag + CS + HERC5 where 15.0% ± 9.8% SD and
10.5% ± 3.5% SD of the cells contained large clusters of
intracellular Gag, respectively (P < 0.0001, Fisher’s exact
test) (Figure 5C). Taken together, these data suggest
that the mechanism of inhibition of HIV-1 Gag particle
production is different in cells expressing CS + HERC5
than in cells expressing CS only.
HERC5 restricts MLV Gag-containing particle production
To assess the specificity of HERC5 for retroviruses, we
tested the ability of HERC5 to restrict Gag particle pro-
duction of the simple retrovirus MLV. Using a similar
Gag particle release assay as that used above for HIV-1
Gag, we found that HERC5 + CS markedly restricted the
release of MLV Gag-containing particles into the super-
natant (Figure 6). Similar to that with HIV-1, Ubp43 co-
expression rescued HERC5-induced restriction of MLV
Gag particle production. HERC5-C994A + CS did not
restrict MLV Gag particle production suggesting that the
E3 ligase activity is also required for MLV restriction as it
is for HIV-1. In contrast with that of HIV-1, expression
of HERC5 + CS caused a substantial accumulation of
intracellular MLV Gag protein. This accumulation was
prevented by co-expression with Ubp43 (Figure 6).
Taken together, these data suggest that HERC5 restricts
Gag particle production from an evolutionarily diverse
retrovirus and that the mechanism involves the E3 ligase
activity of HERC5 for ISG15 conjugation.
HERC5 expression in HIV1-infected patients
To assess the expression of herc5 in HIV-1-infected
patients, we mined the Gene Expression Omnibus data-
base repository http://www.ncbi.nlm.nih.gov/gds for pub-
lished datasets containing gene expression profiles in
HIV-1-infected individuals at various stages of disease
progression. Transcriptional profiling data revealed that
HERC5 and ISG15 RNA expression are significantly
increased in lymphatic tissue during acute HIV-1 infec-
tion in patients with asymptomatic and acute stages of
AIDS and patients with AIDS (Figure 7A) [2]. Significant
increases in HERC5 and ISG15 RNA expression were
observed in monocytes from viremic individuals after
cessation of highly active antiretroviral therapy (HAART)
compared to aviremic patients during HAART (Figure
7B) [3]. HERC5 and ISG15 expression is significantly
increased in primary human PBMCs from seropositive
patients compared to seronegative patients (Figure 7C)
[4]. HERC5 and ISG15 expression is significantly
increased in CD4+ T cells from acutely and chronically
infected patients, but not in non-progressors (Figure 7D)
[32]. HERC5, but not ISG15, is significantly increased in
elite controllers and patients treated with HAART com-
pared to HIV-1 negative patients (Figure 7E) [33].
Furthermore, HERC5 and ISG15 were identified as corre-
lates of protection from HIV-1 infection in controllers
compared to non-controllers (see reference [1]). In all
datasets, there was no significant increase in the expres-
sion of beta actin, except in patients in the acute stages
of AIDS, where a modest increase was observed (Figure
7A). Taken together, these data show that HERC5
expression is significantly increased in patients in the
acute and chronic stages of infection and in patients in
stages of long-term control of infection.
Discussion
Here we have identified HERC5 as an IFN-induced pro-
tein that is able to block an early step of HIV-1 particle
assembly at the plasma membrane. HERC5 and Gag
proteins were found to associate with each other in vitro
and to co-localize within cells. These interactions corre-
lated with the modification of Gag protein with ISG15.
Table 1 Quantification of 10 nm gold particle-labeled anti-p24CA in cells expressing HERC5+CS and HIV-1 Gag
Region Observed gold count, Go Point count, P Expected gold count, Ge Go/Ge Χ
2 Χ
2 as %
Particles+
Plasma membrane
118 189 29 4.0 270.3 85.9
Cytoplasm+
Nucleus
80 875 135 0.6 22.5 7.1
Non-particle+
non-cell
18 335 52 0.3 22.0 7.0
TOTAL 216 1399 216 314.8 100.0
For Χ
2 = 314.8 and df = 2, P < 0.0001 (Χ
2 analysis). The gold labeling distribution is significantly different from random. Only the particles/plasma membrane
region (Go/Ge = 4.0, Χ
2 = 85.9% of total) meets the two criteria for being preferentially labeled ((Go/Ge) > 1 and Χ
2 value ≥ 10% of total).
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Page 10 of 17HERC5 did not alter the trafficking of Gag to the
plasma membrane; however, microscopic analysis
revealed that Gag assembly was blocked at an early
stage. HERC5 was also able to restrict the release of
MLV Gag, showing that HERC5 can restrict an evolutio-
narily diverse retrovirus.
The mammalian Type I IFN response induces several
host factors capable of restricting specific steps of HIV-
1 replication at late stages of its life cycle in the absence
of viral countermeasures; portraying a sophisticated and
redundant defense mechanism (reviewed in [5]).
Recently, TRIM22 has been shown to be a correlate of
HIV-1 infection [34] and can block HIV-1 Gag particle
production by altering intracellular trafficking of Gag to
t h ep l a s m am e m b r a n ea n db yi n h i b i t i n gt r a n s c r i p t i o n
from the HIV-1 long terminal repeat [7,35]. Rhesus
TRIM5a has also been shown to degrade intracellular
HIV-1 Gag polyproteins [36,37]. ISG15 has been shown
to interfere with late stages of HIV-1 Gag budding by
disrupting interactions between Gag and Tsg101 [31]
and between VPS4 and LIP5 [29,30], interactions that
are necessary for membrane scission and virus release.
In the absence of HIV-1 Vpu, the host factor BST-2
(Tetherin) retains mature virions on the cell surface that
are then subsequently endocytosed [38,39].
The HERC5-induced post-translational modification of
Gag is a potentially novel innate defense mechanism
against HIV-1. It is unknown whether the modification
of Gag is a prerequisite or consequence of restriction.
Data presented by Durfee and colleagues (2010) show
that HERC5 co-translationally modifies newly synthe-
sized proteins with ISG15. Although we showed here
that HERC5 interacts with Gag and co-localizes with
Gag in cells, additional experiments are needed to deter-
mine if HERC5 post-translationally modifies newly made
Gag polyproteins and if this modification directly inter-
feres with Gag assembly at the plasma membrane. It is
currently unclear how or why HERC5 accumulates more
in a region near the plasma membrane in the presence
of Gag and the conjugation system. It is possible that
some HERC5 associates with newly synthesized Gag on
the way to the plasma membrane. However, it is also
possible that HERC5 is recruited to regions of Gag
assembly by other mechanisms. Further experiments are
required to determine how and why the localization of
some HERC5 protein changes in the presence of Gag.
The assembly and budding processes of HIV-1 Gag par-
ticles are relatively well understood (reviewed in
[23,40-45]), however much remains to be known about
how the initial HIV-1 Gag bud forms and how the bud
morphs into the “lollipop” structure. It has been suggested
that energetic requirements for membrane distortion,
which is a prerequisite for budding, occurs through the
higher-order oligomerization of Gag molecules and is
mediated through interactions between the interaction-
domain of Gag. It is possible that HERC5 reduces Gag-
Gag interactions below a threshold required to complete
budding. HERC5-induced modification of a small fraction
of Gag monomers may inhibit higher-order oligomeriza-
tion and/or the recruitment of cellular factors due to steric
hindrance of an attached ISG15 molecule. Alternatively,
HERC5 could disrupt interactions with factors that manip-
ulate membrane curvature and initiate or propagate for-
mation of the bud. Such interactions have been observed
between endophilin-2 and MLV Gag, and HIV-1 Gag and
actin [46,47]. Further experiments will be needed to
address these and other possibilities.
Consistent with three previous studies [29-31], we were
able to show that expression of ISG15 together with its
E1 and E2 enzymes (in the absence of HERC5 expres-
sion) restricted Gag particle production without a reduc-
tion in intracellular Gag protein. Our data, together with
data obtained by Okumura A., et al. (2006), Pincetic A.,
et al. (2010) and Kuang Z. et al. (2011), suggest that
HERC5 restriction is distinct from the anti-HIV-1 activ-
ities of ISG15-only expression in that HERC5 induces the
modification of Gag, whereas ISG15 alone does not.
Moreover, HERC5 induces an arrest at an early step of
assembly, whereas the expression of ISG15 alone causes
an arrest at a late stage of budding/release where predo-
minantly immature virions accumulate on the cell surface
in doublet pairs or in chains. Interestingly, the phenotype
resulting from the expression of ISG15 alone resembles
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Figure 6 HERC5 restricts MLV Gag particle production.U 2 O S
cells were co-transfected with pMLV-Gag and either empty plasmid,
pHERC5 + CS, or pHERC5-C994A + CS with or without pUbp43. Gag
particles released into the supernatant and intracellular Gag protein
expression were analyzed by quantitative Western blotting using
anti-MLV antisera or anti-b-actin 48 hours post-transfection.
Numerical values on the blots display the densitometric
quantification of the specified bands after normalization with
b-actin levels.
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Figure 7 HERC5 and ISG15 expression in HIV-1-infected patients. The Gene Expression Omnibus database repository was searched to
identify published transcriptional profiling datasets of HIV-1- infected patient samples. The average relative RNA expression levels of HERC5,
ISG15 and beta actin were compared for each dataset. A, GSE16363 dataset from Li et al. (2009) comparing patients with asymptomatic and
acute stages of AIDS and patients with AIDS. B, GDS2168 dataset from Tilton et al. (2006) comparing monocytes from viremic individuals after
cessation of HAART and aviremic patients during HAART. C, GDS1449 dataset from Ockenhouse et al. (2005) comparing primary human PBMCs
from seropositive patients compared to seronegative patients. D, GDS2649 dataset from Hyrcza et al. (2007) comparing CD4+ T cells from non-
progressors, and acutely and chronically infected patients. E, GSE23879 dataset from Vigneault et al. (2011) comparing elite controllers and
patients treated with HAART. Significance was calculated using Student’s unpaired t test. P values < 0.05 were considered significant.
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Page 12 of 17that observed with HIV-1 p6 mutants where the authors
reported that these virions accumulated on the surface in
doublet pairs or in chains and were largely immature
[48]. The HIV-1 p6 protein regulates the final abscission
step of nascent virions from the cell surface and accom-
plishes this primarily through the recruitment of Tsg101
and other members of the ESCRT complexes. The
expression of ISG15 alone has been shown to interfere
both with the recruitment of Tsg101 to p6 [31] and the
interaction of Vps4 and LIP5, which are needed to pro-
mote the formation of the ESCRT-III-Vps4 double-hex-
amer complex required for membrane scission and virion
r e l e a s e[ 2 9 ] .I ti sp o s s i b l et h a ti nt h ea b s e n c eo fH E R C 5 ,
another restrictive E3 ligase (yet to be identified) can be
utilized, or that the E2-ISG15 complex can ISGylate sub-
strate proteins in an E3 ligase-independent manner.
The ability of HERC5 to target viral proteins is not lim-
ited to HIV-1. We showed here that HERC5 blocked Gag
particle production of an evolutionarily divergent retro-
virus MLV. Interestingly, we found that HERC5 did not
modify MLV Gag with ISG15 to appreciable levels com-
pared to HIV-1 Gag and that HERC5 expression led to a
substantial accumulation of intracellular MLV Gag pro-
tein. The reason for this difference is unclear, but could be
due to differences in the rates of de-ISGylation and/or
protein turnover. HERC5 E3 ligase activity has also been
shown to block the antiviral function of the influenza A
NS1 protein and interfere with the infectivity of human
papillomavirus 16 pseudoviruses [20,21]. Given that
HERC5 is present in several vertebrates, it will be interest-
ing to learn more about the spectrum of pathogens that
can be targeted by HERC5 and the mechanisms underly-
ing its restriction.
Our analysis of transcriptional profiling data of patient
samples from various stages of infection and disease pro-
gression revealed that HERC5 expression is significantly
increased in viremic patients (eg. acute, chronic, and
AIDS). Given our data presented here that HERC5 inhibits
HIV-1 particle production, one standing question is why
HERC5 is not sufficient to suppress HIV-1 infection in
patients who succumb to AIDS? One possibility is that
these patients express non-functional HERC5 variants.
Since we showed that the HERC5-C994A mutant failed to
inhibit HIV-1 particle production, it is plausible that poly-
morphisms in the herc5 gene that perturb the E3 ligase
activity, or other polymorphisms affecting activity of the
HERC5 protein, impact disease progression. For example,
an insertion/deletion polymorphism (rs34457268) has
been identified in humans that leads to a translational fra-
meshift and the production of a truncated HERC5 protein
lacking the Cys994 active site residue.
A small percentage of HIV-1 infected patients remain
asymptomatic for more than 10 years and maintain high
CD4 cell counts without antiretroviral therapy. There are
now several lines of evidence to suggest that these HIV-1
controllers are still infected with pathogenic virus, indicat-
ing that host factors of the innate and adaptive immune
responses may play an important role in limiting HIV-1
replication and disease progression. Intriguingly, our ana-
lysis revealed that HERC5 expression is significantly
increased in the elite controllers of the Vigneault et al.
(2011) dataset, patients who have stable CD4
+ T cell
counts for > 10 years without any clinical signs of disease
progression. Notably, gene transcripts known to be
involved in intrinsic cellular defense against retroviruses,
such as members of the TRIM and APOBEC gene families,
BST2/tetherin, and cyclophilin A, were not expressed dif-
ferently between the elite controllers and the reference
patients [33]. This begs the question of whether HERC5 is
one factor, in addition to others, that can impact disease
progression in these patients. Future work is needed to
determine if HERC5 fits with the classical description of a
cellular restriction factor, whether clinical isolates of HIV-
1 possess HERC5 countermeasures, and whether herc5
gene polymorphisms impact disease progression.
Methods
Ethics Statement
Informed consent was obtained from all subjects according
to the ethics protocol #16682E, approved by The Univer-
sity of Western Ontario Research Ethics Board for Health
Sciences Research Involving Human Subjects (HSREB).
Cells and Cell Lines
Cells were maintained in standard growth medium (Dul-
becco’s Modified Eagle’sM e d i u m( D M E M )f o ra d h e r e n t
cells and RPMI-1640 for suspension cells), supplemented
with 10% heat-inactivated Fetal Bovine Serum (FBS),
100 U/ml Penicillin and 100 μg/ml Streptomycin) at 37°C
with 5% CO2. Cell lines were obtained from American
Type Culture Collection unless otherwise stated. The mur-
ine dendritic cell line DC2.4 was described previously [49].
HOS-CD4/CXCR4 was provided by Dr. F. Bushman (Uni-
versity of Pennsylvania, USA). The following reagent was
obtained through the NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH:
(GHOST (3) R3/X4/R5; Cat. 3943) from Dr. Vineet N.
KewalRamani and Dr. Dan R. Littman [50]. Peripheral
blood mononuclear cells (PBMCs) were isolated from
whole blood from healthy volunteers using a Ficoll Hypa-
que (Sigma) gradient according to the manufacturer’s
instructions.
Plasmids, transfections and antibodies
Plasmids pUbe1L, pUbcH8, myc-tagged ISG15 (pMyc-
ISG15), flag-tagged HERC5 (pHERC5) and flag-tagged
HERC5-C994A (pHERC5-C994A) were kindly provided
b yD r .K .C h i n( G e n o m eI n s t i t u t eo fS i n g a p o r e ) .T h e
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Page 13 of 17promoterless empty vector plasmid pGL3 was purchased
from Promega, p3xFLAG from Sigma, and pUbp43 from
Open Biosystems. pLKO.1/scrambledshRNA was obtained
from Addgene plasmid 1864; sequence 5’ cctaa ggtta
agtcg ccctc gctct agcga gggcg actta acctt agg 3’) [51].
pLKO.1/HERC5shRNA (cat. #RHS4533-NM_016323,
TRCN0000004169) was obtained from Open Biosystems.
The plasmid encoding histidine-tagged ISG15 (pHis-
ISG15) was created from the pMyc-ISG15 template by
amplifying ISG15 using PCR and the primers: forward- 5’
ACG TAA GCT TAC CAT GCA TCA TCA CCA TCA
CCA TGG TGA TCA AAT GGG CTG GGA CCT GAC
GG 3’ and reverse 5’ ACG TCT CGA GTC TAG ATT
A G CT C CG C CC G CC A GG3 ’. The forward primer
encoded a 6× His tag (underlined). The amplified pro-
duct was cloned into pcDNA3.1(+) (Invitrogen) using
HindIII and XbaI. The plasmid encoding codon-opti-
mized Gag (pGag) was obtained through the NIH AIDS
Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH from Drs. Yingying Li, Feng Gao and
Beatrice H. Hahn (p96ZM651gag-opt) [52]. Plasmid
encoding the replication-competent provirus HIV-1 R9
was obtained from Dr. F. Bushman (University of Penn-
sylvania, USA). Plasmid transfections were performed
using standard calcium phosphate transfection for co-
transfections of 3 or more plasmids or Lipofectamine
2000 (Invitrogen). Plasmids were co-transfected at a ratio
of 10:7.5:7.5:7.5:1 for pHERC5 or pHERC5-C994A,
pUbcH8, pUbe1L, pMyc-ISG15 and pGag or pR9 respec-
tively, unless otherwise noted. The following reagents
were obtained through the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID,
NIH: HIV-1 p24 Monoclonal Antibody (183-H12-5C)
from Dr. Bruce Chesebro and Kathy Wehrly [53-55]);
HIV-1SF2 p24 antiserum. MLV antiserum was a gener-
ous gift from Dr. S. Ross (University of Pennsylvania,
USA). Antibodies: anti-HERC5 was obtained from
Abnova, anti-FLAG from Sigma, anti-ISG15 and anti-b-
actin from Rockland, anti-HA from Roche, anti-myc
from Santa Cruz, and anti-ribosomal protein S6 from
Cell Signaling Technology.
Quantification of infectious virus
Clarified supernatants containing virus particles were pel-
leted over a 20% sucrose cushion for 2 hours at 21,000 ×
g. Pellets were lysed for quantitative Western blot analysis
or resuspended in fresh medium and used to infect
GHOST(3) indicator cells. Quantification of infectious
virus release using GHOST(3) indicator cells has been
described previously [50].
Reverse transcription polymerase chain reaction
Total RNA was isolated from cell lysates using the Pure-
link RNA Mini Kit and reverse transcribed using
M-MLV reverse transcriptase according to manufac-
turer’s instructions (Life Technologies). The cDNA was
amplified by PCR using the following primers: HERC5
forward- 5’ C T GG C AC T GT T TA A GA A AC3 ’;
HERC5 reverse- 5’ T C AG C CA A AT C CT C TG3 ’;
HERC3 forward- 5’ ATG TTA TGT TGG GGA TAT
TGG 3’; HERC3 reverse- 5’ T C AG G CC A AA C TA A A
CCC TTC ATA G 3’; b-actin forward- 5’ GGT CAT
CAC CAT TGG CAA TGA GCG G 3’; b-actin reverse-
5’ GGA CTC GTC ATA CTC CTG CTT GCT G 3’.
Amplified DNA were separated on a 1% agarose and
quantified densitometrically using ImageJ 1.43 u 64-bit
version software (NIH, USA).
Immunoprecipitation
For immunoprecipitation, cells were lysed with cold non-
denaturing lysis buffer (1% (w/v) SDS, 50 mM Tris-Cl pH
7.4, 5 mM EDTA pH 8.0, 300 mM NaCl, 0.02% (w/v)
sodium azide with Roche protease inhibitor) for 20 min-
utes. Cyanogen bromide-activated Sepharose beads (GE
Health Care) were swollen in 1 mM HCl for 10 minutes
followed by antibody coupling using either 5 μl of rabbit
anti-p24CA or 1 μl of mouse anti-FLAG (Sigma) per 75 μl
of beads in coupling buffer (0.1 M NaHCO3 pH 8.3 with
0.5 M NaCl) overnight at 4°C. The beads were then
washed three times with coupling buffer to remove excess
antibody. The beads were blocked with blocking buffer
(0.1 M Tris-HCl buffer pH 8.0) for 2 hours at 4°C. The
beads where then washed with 3 cycles of alternating pH
(0.1 M sodium acetate pH 4 with 0.5 M NaCl; 0.1 M Tris-
HCl pH 8.0 with 0.5 M NaCl). The cell lysates were added
to the beads for 1 hour at 4°C. The beads were washed 8
times with non-denaturing lysis buffer and the protein was
eluted with 0.5 mM NaCl.
Western blotting
Clarified supernatants containing virus or Gag-only parti-
cles were pelleted over a 20% sucrose cushion for 2 hours
at 21,000 × g. For cell lysates, cells were detached, centri-
fuged at 350 × g for 5 mins, washed twice with phosphate-
buffered saline (PBS). Pellets were lysed with 1× RIPA buf-
fer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM
EDTA, 1× Complete Protease Inhibitor (Roche), 1% Triton
X-100, 0.1% SDS). For quantitative Western blotting, sam-
ples were mixed with 4× loading buffer (40% Glycerol, 240
mM Tris/HCl pH 6.8, 8% SDS, 0.04% bromophenol blue,
and 5% beta-mercaptoethanol) to a final 1× concentration
and separated on a 10% SDS-PAGE gel. Protein was trans-
ferred to FluorTransW (Pall) membrane by semi-dry
transfer. Western blotting was carried out by blocking the
membrane for 1 hour in Li-cor Blocking Buffer (Li-cor
Biosciences) followed by an ~16 hour incubation with
1:1000 dilution of primary antibody. Detection was carried
out using IRdye-labeled secondary antibody (1:20,000 for
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Biosciences). Densitometric analysis was performed using
ImageJ 1.43 u 64-bit version software (NIH, USA).
Protein identification by mass spectrometry
Gel slices were excised and protein subjected to trypsin
digestion followed by peptide identification by MALDI-
MS using the Applied Biosystems
® 4700 Proteomics
Discovery System. A search of the NCBInr viral database
using Mascot identified HIV-1 Gag protein with > 5
matching peptides and scores > 50.
Purification of histidine-ISG15 tagged proteins
Cells were cultured in 10 cm dishes and co-transfected
with empty vector plasmid or pHERC5, pUbcH8, pUbe1L,
pISG15 and pGag (10:7.5:7.5:7.5:2 ratio respectively) with
or without pUbp43. Nickel pull down of histidine-tagged
ISG15ylated proteins was completed as previously
described [20]. Briefly, cells were lysed with His-lysis buf-
fer (50 mM Tris-Cl [pH 7.4], 300 mM NaCl, 1% Triton-X
100, 10 mM imidazole, 10 mM 2-b-mercaptoethanol) with
5m MN-ethylmaleimide (Sigma), 1 mM PMSF (Sigma),
and a protease inhibitor mixture (Roche). Ni-NTA agarose
(Qiagen) was added to clarified cell extracts and incubated
o v e r n i g h ta t4 ° C .T h eN i - a g a r o s ew a sw a s h e d3t i m e si n
His-lysis buffer and the protein was eluted with 0.5 M
imidazole.
Confocal Immunofluorescence Microscopy
Cells were cultured in 12-well plates on 18 mm coverslips
and co-transfected with pHERC5 (or pHERC5-C994A or
empty vector), pUbcH8, pUbe1L, pISG15 and pGag
(10:5:5.5:1 ratio respectively). Twenty-four hours post-
transfection, the coverslips containing the cells were
washed twice with PF buffer (1× PBS + 1% FBS), fixed for
10 minutes in 1× PBS containing 5% formaldehyde and
2% sucrose, permeabilized in 1× PBS containing 5% NP-40
and then washed twice more with PF buffer. The cover-
slips were incubated with primary antibodies for one hour,
washed 6× with PF buffer, incubated with secondary anti-
bodies (Alexa Fluor 546 anti-mouse or AlexaFluor 488
anti-rabbit, Invitrogen) for one hour and then washed 6×
with PF buffer. Coverslips were mounted onto glass slides
with ~10 μl of Vectashield mounting media with DAPI
(Vector Laboratories) and then sealed with nail polish.
Slides were examined usingaZ e i s sL S M5 1 0c o n f o c a l
fluorescence microscope and images were obtained with
sequential imaging. Spatially-calibrated images were ana-
lyzed using the “Co-localization Threshold” plugin of the
ImageJ 1.43 u 64-bit version software (NIH, USA) for co-
localization using the method of Costes et al. (2004) for
spatial intensity correlation analysis, automatic threshold-
ing and statistical significance testing [56]. The Pearson’s
correlation coefficient of co-localized volumes measures
the correlation between the intensities of the two labels in
the co-localized voxels and is used to express the extent of
co-localization where a value of 1.0 represents perfect
correlation.
Transmission Electron Microscopy
Cells were transfected with pHERC5 or pHERC5-C994A,
pUbe1L, pUbcH8, pMyc-ISG15 and pR9 (10:7.5:7.5:7.5:1
ratio) using calcium phosphate. Forty-eight hours post-
transfection cells were fixed in 2.5% glutaraldehyde in a
0.1 M sodium cacodylate buffer. Cells were washed 3
times in 0.1 M sodium cacodylate buffer. The cells were
fixed in 1% osmium tetroxide in 0.1 M cacodylate buffer
for 1 hour and then washed 3 times in 0.1 M cacodylate
buffer and enrobed in 5% noble agar. Agar was washed 5
times with distilled water then stained with 2% uranyl
acetate for two hours. Agar was then dehydrated with 50%
ethanol for 15 minutes then dehydrated in 70% ethanol
overnight at 4°C. The next day the agar was dehydrated
with 85% then 95% ethanol for 15 minutes each. The agar
was dehydrated in propylene oxide for 15 minutes and
added to a 1:1 ratio of epon resin/propylene oxide for 3
hours followed by incubation in a 3:1 ratio of epon resin/
propylene oxide overnight at 4°C. The following day, the
agar was incubated in pure epon resin for 6 hours. Lastly,
the samples were kept at 60°C for 2 days. Slices were cut
and visualized using a Philips EM 410 equipped with high
resolution 35 mm film output. Developed photos were
digitized using an Epson Expression 1680 scanner.
For immunogold staining, U2OS cells were fixed in 3%
paraformaldehyde, 0.025% gluteraldehyde, in 0.1 M caco-
dylate (CAC) buffer adjusted to pH 7.4 for two hours.
Cells were then washed with 0.1 CAC buffer. Cells were
later enrobed in 5% noble agar. Solidified agar and cell
mixture was dehydrated in 50, 70, 85, 95, 2× 100% etha-
nol respectively. Samples were rotated in a 1:1 LR white
resin:100% ethanol then in pure LR white. The sample
was placed in a gelatine capsule and placed in an oven at
50°C for 24 hours. Samples were cut and placed on nickel
grids. Grids were blocked with a 0.2 uM filtered 1% BSA
PBS Buffer (10.4 mM Na2HPO4,3 . 2m MK H 2PO4,
20 mM NaN3, 150 mM NaCl, 1% BSA, pH 7.4) and incu-
b a t e da tr o o mt e m p e r a t u r ef o r2h o u r sw i t h0 . 2 5m g / m l
anti-p24CA (1:20 dilution). Samples were washed and
incubated at room temperature for 2 hours with second-
ary goat anti-mouse IgG colloidal 10 nm gold-conjugated
antibody (Invitrogen cat# A31561) at a dilution of 1:30.
Samples were washed with BSA-PBS buffer and then
with dH20. Samples were stained with 2% uranyl acetate
for 5 minutes and then washed with dH20.
Statistical Analyses
GraphPad Prism v5.03 was used for all statistical analyses
stated in the text. P values and statistical tests were stated
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were deemed to be significant. Immunogold-labeling
quantification: Quantification of immunogold localiza-
tion on the electron microscopic thin sections was per-
formed as described previously [57]. Gold particles were
counted for each field of view and scored as falling on
one of three regions of interest: 1) HIV-1 Gag particles
and plasma membrane; 2) cytoplasm and nucleus; and 3)
not containing particles or cells. The plasma membrane
was defined as the outer most edge of the cell to a dis-
tance 100 nm inside the cell. 100 nm was chosen since
this is approximately the diameter of a mature HIV-1 vir-
ion. The resulting numerical frequency distribution (G0)
represents the ‘observed’ distribution [58]. The ‘expected’
or ‘predicted’ distribution of gold particles was deter-
mined using a randomly positioned lattice of test points
(P) superimposed on each field of view. This was done by
viewing the ‘grid’ feature in Adobe Photoshop CS3 for
each image. The resulting distribution of test (or ‘grid’)
points represents that which would be expected if gold
particles were scattered randomly across the cell [58].
The number of points that fell on each of the three
regions of interest were scored. The expected number of
gold particles (Ge) for each region was calculated using
the formula: Ge = P*(total Go)/(total P). The correspond-
ing partial X
2 for each region was calculated from the
observed and expected gold counts as: X
2 =( G o-Ge)
2/Ge.
If the total X
2 value for the given degrees of freedom (df)
(given by 2-1 columns × 3-1 regions) indicated that the
observed and expected distributions were significantly
different, the null hypothesis of no difference from ran-
dom labeling was rejected. Preferentially labeled regions
were identified on the basis of satisfying two criteria.
First, the Go/Ge was > 1 and, secondly, the corresponding
partial X
2 value accounted for a substantial proportion
(≥ 10%) of the total X
2 value [58].
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